Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 299

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1
Chunk 299
---

covering the licensed products. The licensed patent rights are expected to extend through 2043. We expect additional patent terms may
be awarded, including additional patent terms based on the time for regulatory review of drug products. There are no up-front, execution,
or milestone payments required under the license agreement. Further, no payments have been made to date under the agreement. We are also
required to pay an 8% royalty on net sales or revenue in exchange for an exclusive, worldwide license to patent rights, and we may bring
suit in our own name to enforce our patent rights under the license agreement. In the event we are unable to enforce our rights under
the agreement or are unable to detect unauthorized use of our intellectual property, we may lose the benefit of the licensed rights used
to commercially develop Telomir-1. MIRALOGX will control the prosecution of the patent applications for Telomir-1.

22

If
third parties claim that our intellectual property, products, processes, or anything else used by us infringes upon their intellectual
property, our operating profits could be adversely affected.

There
is a substantial amount of litigation, both within and outside the U.S., involving patent and other intellectual property rights in the
pharmaceutical industry. We may, from time to time, be notified of claims that we are infringing upon patents, trademarks, copyrights,
or other intellectual property rights owned by third parties, and we cannot provide assurances that other companies will not, in the
future, pursue such infringement claims against us, our commercial partners or any third-party proprietary technologies we have licensed.
If we were found to infringe upon a patent or other intellectual property right, or if we failed to obtain or renew a license under a
patent or other intellectual property right from a third party, or if a third party that we were licensing technologies from was found
to infringe upon a patent or other intellectual property rights of another third party, we may be required to pay damages, including
damages of up to three times the damages found or assessed, if the infringement is found to be willful, suspend the manufacture of certain
products or reengineer or rebrand our products, if feasible, or we may be unable to enter certain new product markets. Any such claims
could also be expensive and time consuming to defend and divert management’s attention and resources. Our competitive position
could suffer as a result. In addition, if we have declined or failed to enter into a valid non-disc